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and AKT. Recently, the plasma membrane Ca2+-ATPase PMCA4b wasinduced ischemia of an organ or limb confer protective effects to other
distant organs and tissues (Heusch et al., 2015). RPC has shown promise
in clinical trials as a strategy to protect against potentially injurious
exposures, including the prevention of radiographic contrast-induced
kidney damage, a serious clinical problem (Hu et al., 2016). Though an
intriguing phenomenon, the mechanisms mediating RPC are not well-
understood. In this issue of EBioMedicine, Wang et al. report that the
37 kDa protein renalase mediates RPC-induced protection against
contrast-induced nephropathy (CIN) in a rat model, and that siRNA
knockdown of renalase expression in the kidney abolishes this protec-
tion (Wang et al., 2016). The authors ﬁnd that renalase expression in
the kidney is upregulated by RPC, and present evidence that this is me-
diated by circulating TNFα released into the bloodstream during RPC.
These data add to a growing number of studies showing that
renalase has a powerful cytoprotective function, including recent stud-
ies showing that this function of renalase is exploited by malignant
cells as a survival strategy (Hollander et al., 2016; Guo et al., 2016; Wu
et al., 2011). Renalase, named for its discovery as a protein secreted by
the kidney, exhibits fascinating biology (Xu et al., 2005). It is an intracel-
lular and extracellular ﬂavoprotein, circulates in blood at a concentra-
tion of approximately 5 μg/ml, and functions both as a ﬂavoenzyme
and as a cytokine. Its intracellular role has remained unclear, although
it has been assumed that its enzyme function is likely important there.
Recently an enzymatic role in converting dihydro forms of ßNAD(P)H
tometabolically available ßNAD(P)Hwas described, and it is postulated
that intracellular renalase has a metabolic role (Beaupre et al., 2015).
Whether this role relates speciﬁcally to renalase cytoprotective effects
remains unknown, and indeed the relative contributions of intracellular
versus extracellular renalase to its cytoprotective function are also
unclear.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.05.017.
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and it has now been established in multiple studies that speciﬁc short
renalase-derived peptides, devoid of enzyme activity, can confer the
same cytoprotection as does full-length renalase (Guo et al., 2016;
Hollander et al., 2016; Wang et al., 2014). Strong evidence links this to
the ability of renalase, and speciﬁc renalase-derived peptides, to acti-
deﬁned as a receptor for renalase and for the bioactive renalase-
derived peptides (Wang et al., 2015). PMCA4b is a low-capacity calcium
pump thought to function primarily as part of a signaling complex.
Genetic knockdown of PMCA4b, or speciﬁc pharmacological inhibition,
abolishes renalase and renalase peptide-induced signaling and concom-
itantly their cytoprotective effects, thus establishing a crucial role of
PMCA4b in a receptor-mediated extracellular renalase function.
In the study by Wang et al., RPC-induced renalase expression in the
kidney was attributed to NFkB signaling induced by TNFα, and was
blocked by a TNFα inhibitor. This is of signiﬁcant interest in that a role
for renalase in modulation of inﬂammation and immune surveillance
has been postulated, potentially as a mechanism whereby tumors es-
cape the immune system (Hollander et al., 2016). Indeed, Wang et al.
show that RPC reduced MCP-1 expression and macrophage inﬁltration
of the kidney after contrast exposure, and that siRNA knockdown of
renalase abolished this anti-inﬂammatory effect of RPC. The regulation
of renalase expression is an area of active investigation, and it has
been shown that STAT3 induces renalase transcription. As such, a role
for extracellular renalase, signaling via STAT3, in upregulating intracel-
lular renalase expression in a positive feedbackmanner has been postu-
lated, and ﬁts with data demonstrating that intracellular renalase levels
vary in the same direction as extracellular renalase (Hollander et al.,
2016). Whether extracellular renalase acting via receptor-mediated
signaling alters other aspects of intracellular renalase biology,
inﬂuencing post-translational modiﬁcations, enzyme activity, cellular
location, or even secretion, is also unknown and of signiﬁcant interest.
In the study byWang et al., siRNA knockdown of renalase in the kid-
ney abolished the RPC effect. This would at ﬁrst glance appear attribut-
able to decreased intracellular renalase, as this is where the siRNA
works, but it is also possible that siRNA knockdown signiﬁcantly de-
creased extracellular renalase levels and interrupted local paracrine or
autocrine loops. Further, the kidney is a major source of circulating
renalase, and it is possible siRNA knockdown of renalase expression in
the kidney led to a signiﬁcant decrease in circulating renalase, although-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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previously reported that administration of recombinant renalase also
protects against CIN, and it has been shown in other models of renal
injury that recombinant renalase and the renalase-derived peptides
are both highly protective, all supporting a crucial role of extracellular
renalase-mediated signal transduction in renal protection following
insult (Wang et al., 2014). However, this effect is attenuated in renalase
deﬁcient mice, suggesting an important role of intracellular renalase in
mediating the ultimate cytoprotective effects of extracellular renalase.
This current study adds substantively to a growing literature
documenting a powerful cytoprotective function of renalase, establishes
for the ﬁrst time a vital role of renalase in RPC in the kidney, and
establishes a previously unknown mechanism whereby induced
peripheral ischemia leads to the release of TNFα which then induces
RPC in the kidney by a NFκB-mediated upregulation of renalase expres-
sion.Whether this is a sharedmechanismmediating RPC in other organs
will require further investigation, but this study stands as a signiﬁcant
contribution to our further understanding of what remains a somewhat
enigmatic but biologically powerful protein.
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